Survodutide - Dragon Pharma

Survodutide (BI 456906) is a novel dual agonist targeting both glucagon and GLP-1 receptors, designed for obesity treatment. By stimulating the glucagon receptor it promotes gluconeogenesis, glycogenolysis, and lipolysis, while its GLP-1 receptor activity reduces gastric emptying and suppresses appetite. In trials, for long term obesity management and metabolic improvements there have been promising outcomes that surpass those seen with semaglutide suggesting a breakthrough, in the field. In a phase 2 trial, survodutide reduced body weight in a dose-dependent manner, with doses of 2.4 mg or higher inducing clinically significant weight loss in over half the participants within 8 weeks, offering a promising future treatment for obesity.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Survodutide by Dragon Pharma, consult with your doctor or healthcare professional.